



For further information on the MVVC project,
please go to www.malariavvconsortium.eu
or email babatunde.imoukhuede@euvaccine.eu
For further information about EVI,
please go to www.euvaccine.eu
or email odile.leroy@euvaccine.eu

Malaria Vected Vaccines Consortium

Malaria Vectored Vaccines Consortium

The Malaria Vectored Vaccines Consortium is made up of eight partners; European Vaccine Initiative (EVI, Universitäts Klinikum Heidelberg, Germany), The University of Oxford (UOXF, UK), Vienna School of Clinical Research (VSCR, Austria), Okairos s.r.l, (Italy), Centre National de Recherche sur le Paludisme (CNRFP, Burkina Faso), Kenya Medical Research Institute (KEMRI, Kenya), MRC Gambia (The Gambia), and Université Cheikh Anta Diop (UCAD, Senegal).

Coordination, Funding, and Timelines:

The MVVC project is a four year project coordinated by EVI and is funded by EDCTP (European and Developing Countries Clinical Trials Partnership) and co-funded by the following European Union Member States government agencies: MRC UK, Irish Aid, Sida SAREC, and the Austrian Foreign Ministry. The project commenced on the 1st of November, 2009 and will end on the 31st of October, 2013. The MVVC project tasks are divided into four work packages (WP), each of which is headed by a designated WP leader: WP1 Project Management (Babatunde Imoukhuede, EVI), WP2 Clinical Trials (Kalifa Bojang, MRC Gambia), WP3 Capacity Building (Sodiomon Sirima, CNRFP), and WP4 Networking (Philip Bejon, KEMRI).

Clinical Trials

It is proposed that three clinical trials will be conducted; two Phase I safety and immunogenicity clinical trials and one Phase Ib multi-centre efficacy clinical trial. The candidate malaria vaccines, AdCh63 multiple epitope (ME)-thrombospondin-related adhesion protein (TRAP) and Modified Vaccinia Ankara (MVA) virus ME-TRAP (MVA ME-TRAP), will be tested in a prime-boost vaccination strategy. Vaccine doses will be administered eight weeks apart. Phase Ib clinical trials will commence in Kilifi, Kenya, and Sukuta, The Gambia in Q2 2010. There are two further potential sites in Senegal and Burkina Faso.

Capacity Building

The MVVC promotes capacity-building through infrastructure upgrading as well as training of African scientists and development of clinical trials sites, networking, and the conduct and monitoring of clinical trials. This will enable the formation of a network of European and African partners that will work together to efficiently conduct future clinical trials of new interventions.



Location of the clinical trial sites (indicated by red circles) and potential trial sites (indicated by blue circles).



MVVC kickoff meeting held on the 1st of November, 2009. Pictured, from left to right: (back row) Adrian Hill (UOXF), Philip Bejon (KEMRI), Sten Larsen (EVI), Nathalie Imbault (EVI), Gabriela Schreyer (VSCR), Peninah Sopei (KEMRI), Babatunde Imoukhuede (EVI); Front row: Badara Cisse (UCAD), Issa Nebie (CNRFP), Sodiomon Sirima (CNRFP), Deborah Mogaka (KEMRI), and Kalifa Bojang (MRC Gambia).